Sign inJoin waitlistJoin the waitlist

Devalingam Mahalingam

Professor, Feinberg School of Medicine · Feinberg School of Medicine

Credentials: · · · · · ·

History

Feinberg School of Medicine
Present

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine
Until 2009
National University of Ireland Galway
2000

Research

The Landscape of Targeted Therapies in TNBC
Review · Cancers · 2020 · 358 citations
Targeting HSP90 for cancer therapy
Review · British Journal of Cancer · 2009 · First of 6 authors · 254 citations
Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor…
Autophagy · 2014 · First of 12 authors · 252 citations

FG
Francis Giles
31 papers
John Sarantopoulos
19 papers
Kevin Kelly
17 papers
RS
Ronan Swords
13 papers · 11 as a fellow
Sukeshi Arora
13 papers · 3 as a fellow
AM
Alain Mita
12 papers
Mary Mulcahy
12 papers
Benedito Carneiro
10 papers
MM
Monica Mita
10 papers
Al Benson
7 papers
Swaminathan Iyer
7 papers
Young Chae
7 papers

Grants

The Robert H. Lurie Comprehensive Cancer Center
National Cancer Institute · P30
Project lead · $3.4M · Northwestern University
1997–2030
North American Star Consortium
National Cancer Institute · UM1
PI · $12.9M · University Health Network
2014–2027
Inhibition of Autophagy: A Novel Therapeutic Strategy for Advanced Solid Tumors
National Cancer Institute · R21
Contact PI · $321.5K · University of Texas Hlth Science Center
2009–2013

Clinical trials

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
Principal investigator · Recruiting · Phase 1, Phase 2
Northwestern University
2026–2030
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
Principal investigator · Recruiting · Phase 1, Phase 2
Devalingam Mahalingam
2026–2031
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
Principal investigator · Recruiting · Phase 2
Northwestern University
2024–2030
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Principal investigator · Recruiting · Phase 2
Northwestern University
2023–2030